← GLP-1 receptor agonists × all-cause mortality

TrialDiabetes, obesity & metabolism2023

Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial.

João Sérgio Neves et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 2023

Range includes no effect

No clear effect on deaths

1.4×1× to 2×

Bigger than 8 in 10 for all-cause mortality

As reported

IRR 1.41, 95% CI 0.98–2.04 · the paper's word: All-cause mortality

Range includes no effect

No clear effect on deaths

1.8×0.9× to 3.4×

Bigger than 9 in 10 for all-cause mortality

As reported

IRR 1.76, 95% CI 0.92–3.37 · the paper's word: All-cause mortality

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with more deaths

1.9×1.2× to 2.9×

Bigger than 9 in 10 for all-cause mortality

As reported

IRR 1.86, 95% CI 1.21–2.85 · the paper's word: All-cause mortality

Correlation · may be no link

No clear link with deaths

−38%−69% to +23%

Bigger than 9 in 10 for all-cause mortality

As reported

IRR 0.62, 95% CI 0.31–1.23 · the paper's word: All-cause mortality

Four numbers in the abstract

the abstract, start to end

… Association (NYHA) Class III to IV (IRR 1.86, 95% CI 1.21-2.85) than in those in NYHA Class I to II (IRR 0.62, 95% CI 0.31-1.23; interaction …

… 143 events, incidence rate ratio [IRR] 1.41, 95% confidence interval [CI] 0.98-2.04; P = 0.064) and total arrhythmias (21 vs. 39, IRR 1.76, 95% CI 0.92-3.37; P = 0.088).

← favours treatmentfavours comparator →

could be chance

All-cause mortality

IRR 1.861.21–2.85

All-cause mortality

IRR 1.410.98–2.04

All-cause mortality

IRR 0.620.31–1.23

All-cause mortality

IRR 1.760.92–3.37

GLP-1 receptor agonistsAll-cause mortality

GLP-1 receptor agonists × all-cause mortalityhelps?replicated

unlikelylikely

0.880.88 without it

← favours treatmentfavours comparator →

this papermore certainless certain

1 / 6

34 papers cite it

2023

2024

2025

2026

this paperpooled ittrialcites it

Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial.

What the trial testedas reported · 2023

No clear effect on deaths

No clear effect on deaths

What moved togetherboth groups pooled, not the treatment’s effect

Went with more deaths

No clear link with deaths

Four numbers in the abstract

Where each one falls

Only randomized results vote

Where it lands on the map

What it changes

Among 10 other studies

34 papers cite it